METHODS: Participants were eligible when diagnosed with intermediate risk, unilateral clinically significant localised prostate cancer, fit for either RP or PA. Pre-biopsy mpMRI and targeted biopsy or template guided biopsies were compulsory before randomization to either RP or PA. Target accrual for the feasibility phase was 80 patients over 18 months. Follow-up involved regular PSA measurements and, in the focal therapy arm, mpMRI and targeted biopsies of any suspicious areas. Quality of life data were measured at six weeks and three monthly intervals.
INTRODUCTION AND OBJECTIVES: Determination of biochemical (BCR) recurrence in patients who undergo primary focal cryosurgery (PFC) for organ confined prostate cancer (PCa) is controversial. We aim to evaluate prostate specific antigen (PSA) trends in post PFC patients.
METHODS: A single-center retrospective review of patients from our IRB-approved database who underwent PFC was performed. Patients were followed with serial PSAs and BCR was determined using the Phoenix (PD: PSA nadir + 2 ng/ml) and Stuttgart (SD: PSA nadir + 1.2 ng/ml) definitions. PSA bounce was assessed using 2 different definitions (B1: increase in PSA of 0.4 in first 6 months and any drop thereafter, B2: increase in PSA of !0.2 above nadir and then a drop to/ below nadir) Age, prostate volume, D 0 Amico risk, Gleason score, PSA variables and kinetics overtime were assessed between those who experienced BCR versus not. Various PSA permutations were analyzed.
RESULTS: 123 (94.6%) consecutive patients who had >1 PSA follow-up values were included in our analysis. Median (range) age and follow-up time was 66 (48-82) years and 19 (6.3-68.6) months respectively. 11 (8.9%, 7B1; 4B2) patients experienced PSA bounce and a median percent drop in first post-PFC PSA of 80.0 (0.0-98.7) was not associated with BCR, p¼0.301. PSA values in both groups increased over time but the rate of change was significantly higher in patients who experienced BCR compared to those who did not [median PSA velocity: 0.1 vs 0.04, p¼0.003]. Other PSA variables associated with experiencing BCR were higher pre-PFC PSA (7.2 vs 5.4 ng/ml, p¼0.003) and higher PSA nadir (1.3 vs 1 ng/ml, p¼0.012).
CONCLUSIONS: Higher PSA velocity, nadir and pre-PFC PSA may help raise suspicion for BCR. In the future with validation, these variables could serve as the components of PFC-specific BCR criteria.
Source of Funding: Department of Urology, Winthrop
University Hospital.
PD56-10 UROLOGIST'S PRACTICE PATTERNS AND PREFERENCES REGARDING FOCAL THERAPY FOR PROSTATE CANCER
Amit L Jain*, Abhinav Sidana, Mahir Maruf, Brian Calio, Dordaneh Sugano, Bradford Wood, Peter Pinto, Bethesda, MD INTRODUCTION AND OBJECTIVES: Focal therapy (FT) for localized prostate cancer (PCa) has been shown to have encouraging short term oncological outcomes, excellent preservation of functional outcomes and is increasing in popularity in Urologic community. We aim to evaluate the preferences and practice trends among urologists regarding this upcoming treatment strategy.
METHODS: A 20 item online questionnaire was designed to collect information on urologists' views and use of focal therapy. The survey was sent to the members of the Endourological Society (ES) and the American Urological Association (AUA). Multivariate logistic regression analysis was done to determine predictors for utilization of FT.
RESULTS: A total of 425 responses were received [AUA: 342, ES: 83]. Mean age of respondents was 53(AE11.3) years. Although half of the respondents (50.8%) believed FT to be moderate to extremely beneficial in the treatment of PCa, only 24.2% (103) of the respondents currently utilize FT in their practice. Of the respondents who were fellowship trained in urologic oncology were more likely to consider FT to be moderately to extremely beneficial (p<0.001). Surgeon's experience (practice for more than 15 years) (p ¼ 0.031) was the only independent predictor for utilizing FT in localized PCa. While the most common setting for utilization of FT was in patients with unilateral intermediate risk (72.8%) PCa, a small percentage of respondents also used FT for patients with unilateral high risk PCa and bilateral intermediate risk (21.3% and 10.6% respectively). The most common FT modality was Cryoablation in 58% followed by High Intensity Focused Ultrasound in 44.6%. Most common reasons for not using focal therapy were the lack of belief in 'index lesion theory' (203) (63%) followed by the lack of experience (133) (41.3%). About 57.6% would use FT more often in an office or outpatient setting if they had access to reliable and cost effective options. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1119
